Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Clinical Line Focus
Snapshot: 2026-10-21
Relapsed / Refractory Multiple Myeloma (RRMM) Trials Landscape
Relapsed/refractory multiple myeloma (RRMM) represents the largest proportion of active interventional clinical trials in China, featuring next-generation CAR-T, bispecific antibodies, ADCs, and novel small molecules.
As of 2026-10-21, there are 48 active interventional trials dedicated to this patient population in China.
Active Trials
48
Provinces
30
Centers
467
Clinical Characteristics & Guidance
For patients refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies, novel target clinical trials offer renewed avenues toward remission.
Screening criteria evaluate prior lines of therapy, refractoriness status, and vital organ function scores.
Leading Chinese medical centers possess extensive clinical expertise in managing specialized toxicities such as CRS and ICANS.
Active Studies (48)
Population synthesized by CMDNShowing 50 published English records of 48 registry trials.
Phase IIICTR20262221
RecruitingA Phase III, Randomized Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy (Including an Anti-CD38 Antibody and Lenalidomide)
Population: Relapsed/refractory
Target: Trispecific antibody targeting BCMA, GPRC5D, and CD3
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center、Shanghai Fourth People's Hospital 等 222 家中心
Phase ICTR20253656
RecruitingA Phase I Clinical Study Evaluating the Safety and Pharmacokinetics of Subcutaneous Formulation of TQB2934 for Injection in Participants with Malignant Plasma Cell Neoplasms
Population: Relapsed/refractory
Target: Bispecific antibody targeting BCMA×CD3
Study Sites: Zhongshan Hospital, Fudan University、The Second Affiliated Hospital of Soochow University、The First Affiliated Hospital of Xi'an Jiaotong University、Nanjing Drum Tower Hospital 等 14 家中心
Phase Ib/IIaCTR20241633
RecruitingAn Open-label, Parallel-controlled, Multicenter Phase Ib/IIa Clinical Study on the Efficacy and Safety of Puyistat Mesylate for Injection Combined with Pomalidomide Capsules and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Small-molecule chemosensitizer (HDAC inhibitor)
Study Sites: West China Hospital of Sichuan University、Peking University People's Hospital、Henan Cancer Hospital、The First Affiliated Hospital, Zhejiang University School of Medicine 等 11 家中心
Phase INCT06644118
RecruitingAn Early Exploratory Clinical Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Dual-target CAR-T cell therapy targeting GPRC5D and BCMA
Study Sites: Beijing Gobroad Hospital
Phase IIICTR20253414
RecruitingA Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone Versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: Novel monoclonal antibody targeting CD38
Study Sites: The First Affiliated Hospital of Soochow University、Beijing Chaoyang Hospital, Capital Medical University、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Tianjin Medical University Cancer Institute & Hospital 等 78 家中心
Phase ITM20260016
RecruitingA Phase I Study of In Vivo CAR-T Therapy for Advanced Malignant Tumors (Multiple Myeloma, Lymphoma, Leukemia, Solid Tumors)
Population: Relapsed/refractory
Target: In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5
Study Sites: Cancer Hospital, Chinese Academy of Medical Sciences
Phase I/IIaCTR20223160
RecruitingA Multicenter, Non-Randomized, Open-Label Phase I/IIa Clinical Study Evaluating the Safety, Tolerability, and Efficacy of ICP-490 Monotherapy and in Combination with Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Oral small-molecule "molecular glue" degrader
Study Sites: Peking University People's Hospital、Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine、Shengjing Hospital of China Medical University、Henan Cancer Hospital 等 6 家中心
Phase IIICTR20233883
RecruitingAn Open-Label, Two-Arm, Multicenter, Randomized, Phase III Study Evaluating the Efficacy and Safety of ELRANATAMAB (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Study Participants with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible or Deferred Transplant
Population: Newly diagnosed/Relapsed/refractory
Target: BCMA × CD3 bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center 等 17 家中心
Phase I/IIaCTR20233309
RecruitingA Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characteristics of KQ-2003 CAR-T Cells in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Autologous BCMA/CD19 dual-targeting CAR-T
Study Sites: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Nanchang University、Peking University First Hospital、Henan Cancer Hospital 等 10 家中心
Phase IICTR20202322
RecruitingAn Open-Label, Single-Arm Phase II Clinical Study Evaluating CX13-608 in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Small molecule targeted drug
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Renji Hospital, Shanghai Jiao Tong University School of Medicine、The First Affiliated Hospital, Zhejiang University School of Medicine、Peking University Third Hospital 等 10 家中心
Phase IICTR20230238
RecruitingA Phase II, Open-label, Single-arm, Multicenter Clinical Study Evaluating the Efficacy and Safety of BCMA-targeted Chimeric Antigen Receptor T-cell Injection (CART-BCMA) in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: BCMA-targeted CAR-T cell therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital、Affiliated Hospital of Hebei University 等 25 家中心
Phase IIICTR20223338
RecruitingA Phase 3, 2-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Population: Relapsed/refractory
Target: Next-generation "molecular glue" degrader (CELMoD)
Study Sites: Beijing Chao-Yang Hospital, Capital Medical University (East Campus)、Xi'an International Medical Center Co., Ltd.、Peking University First Hospital、Beijing Chao-Yang Hospital, Capital Medical University (West Campus) 等 32 家中心
Phase ICTR20241358
RecruitingA First-in-Human (FIH), Open-Label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Humanized GPRC5D-BCMA-CD3 Trispecific Antibody SIM0500 in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D × BCMA × CD3 trispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)、Sun Yat-sen University Cancer Center、The First Affiliated Hospital, Zhejiang University School of Medicine、Beijing Chaoyang Hospital, Capital Medical University 等 7 家中心
Phase ICTR20241210
RecruitingA Multicenter, Open-Label Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HMPL-506 in Hematologic Malignancies
Population: Relapsed/refractory
Target: Small molecule targeted drug
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Nanfang Hospital of Southern Medical University、Qilu Hospital of Shandong University、Shengjing Hospital of China Medical University 等 13 家中心
Phase IIICTR20230801
RecruitingAn Open-Label, Single-Arm, Multicenter Clinical Trial Evaluating the Efficacy and Safety of Pomalidomide Capsules Combined with Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Pomalidomide
Study Sites: Beijing Chaoyang Hospital, Capital Medical University、Puyang Oilfield General Hospital、Shangqiu First People's Hospital、Puyang Anyang District Hospital 等 28 家中心
Phase IIICTR20241656
RecruitingA Randomized Controlled Phase III Clinical Study of Equecabtagene Autoleucel Injection in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: CAR-T
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine、Ruijin Hospital, Shanghai Jiao Tong University School of Medicine、Peking Union Medical College Hospital, Chinese Academy of Medical Sciences 等 28 家中心
Phase ICTR20243438
RecruitingA Phase I Clinical Study of CBG002 CAR-T Cell Injection in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: BCMA-targeting CAR-T cell therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Sun Yat-sen University Cancer Center
Phase I
RecruitingA Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of CR-2011 in Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: In vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA (based on mRNA-LNP technology)
Study Sites: Cancer Hospital Chinese Academy of Medical Sciences
Phase ICTR20241570
RecruitingA Multicenter, Open-label, Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Antitumor Efficacy of YKST02 in the Treatment of Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: BCMA × CD3 bispecific antibody
Study Sites: Beijing Chaoyang Hospital, Capital Medical University、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center、Harbin Medical University Cancer Hospital 等 13 家中心
Phase I/IICTR20254042
RecruitingA Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HP-001 Capsules Combined with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Small-molecule chemical drug
Study Sites: West China Hospital, Sichuan University、Henan Cancer Hospital、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine 等 20 家中心
Phase ICTR20221007
RecruitingA Phase I Clinical Trial of HRS-3738 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Population: Relapsed/refractory
Target: Small molecule oral targeted drug / Next-generation EED (embryonic ectoderm development protein) inhibitor
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Henan Cancer Hospital、Shanxi Province Cancer Hospital 等 37 家中心
Phase ICTR20230879
RecruitingA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KYS202002A Monoclonal Antibody Injection in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Recombinant humanized anti-CD38 monoclonal antibody
Study Sites: Beijing Chaoyang Hospital, Capital Medical University、Shengjing Hospital of China Medical University、Zhongshan Hospital, Fudan University、Sun Yat-sen University Cancer Center 等 7 家中心
Phase IIICTR20253381
RecruitingA Randomized, Controlled, Multicenter, Open-Label Phase III Study Evaluating the Efficacy and Safety of QLS32015 for Injection Monotherapy Versus Investigator's Choice of Regimen in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: GPRC5D/CD3 bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital、First Affiliated Hospital of Kunming Medical University、Yunnan Cancer Hospital 等 82 家中心
Early Exploratory Clinical StudyNCT07622862
RecruitingAn Early Exploratory Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of BCMA/GPRC5D Dual-Targeted Allogeneic Universal CAR-T Cell Injection (DQ1001) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: Allogeneic universal CAR-T targeting BCMA/GPRC5D
Study Sites: Zhongshan Hospital, Xiamen University
Phase Ib/IICTR20252876
RecruitingAn Open-Label, Multicenter Phase Ib/II Clinical Trial Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GR1803 Injection in Combination with an Anti-CD38 Monoclonal Antibody in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received at Least 1 Prior Line of Therapy (Including Lenalidomide and a Proteasome Inhibitor)
Population: Relapsed/refractory
Target: Novel bispecific antibody targeting BCMA (GR1803)
Study Sites: The First Affiliated Hospital of Xi'an Jiaotong University、Shanghai Fourth People's Hospital Affiliated to Tongji University、Xiangya Hospital Central South University
Phase ICTR20262569
RecruitingA Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of 6MW5311 in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and Multiple Myeloma
Population: Relapsed/refractory
Target: LILRB4 and CD3 bispecific antibody
Study Sites: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University 等 8 家中心
Phase ICTR20233717
RecruitingA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of GLB-002 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Population: Relapsed/refractory
Target: Molecular glue degrader
Study Sites: Peking University Cancer Hospital、Henan Cancer Hospital、Jiangxi Cancer Hospital、Tianjin Medical University Cancer Institute and Hospital 等 13 家中心
Phase ICTR20240189
RecruitingA Clinical Study of the Safety, Tolerability, and Preliminary Efficacy of SWK001 in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Autologous BCMA/CD19 dual-targeting CAR-T
Study Sites: The First Affiliated Hospital of USTC
Phase I/IICTR20243384
RecruitingA Phase I/II, Multicenter, Open-Label Study of IBI3003 in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Trispecific antibody targeting GPRC5D, BCMA, and CD3
Study Sites: Zhongshan Hospital, Fudan University、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Xi'an Jiaotong University、The Affiliated Hospital of Xuzhou Medical University 等 23 家中心
Phase I/IICTR20241689
RecruitingA Phase I/II, Open-Label, Multicenter, Modular Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 Monotherapy or in Combination with Anticancer Agents in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Antibody-drug conjugate (ADC)
Study Sites: Peking University People's Hospital、Shengjing Hospital of China Medical University (The Second Affiliated Hospital of China Medical University)、Sun Yat-sen University Cancer Center、The Third Xiangya Hospital of Central South University
Phase I
RecruitingAn Early Exploratory Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of CD19- and/or BCMA-Positive B-Cell Malignancies
Population: Relapsed/refractory
Target: CD19, BCMA dual-target in vivo CAR-T
Study Sites: Chinese PLA General Hospital (301 Hospital)
Phase IICTR20250778
RecruitingAn Open-Label, Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of F182112 in Combination with Different Dosing Regimens for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Recombinant Humanized Anti-BCMA/CD3 Bispecific Antibody for Injection
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Bengbu Medical University、The First Affiliated Hospital of Chongqing Medical University、Gansu Provincial Hospital 等 44 家中心
Phase ICTR20244043
RecruitingA Phase I Clinical Study Evaluating the Tolerability and Pharmacokinetics of TQB2029 for Injection in Participants with Multiple Myeloma
Population: Relapsed/refractory
Target: Bispecific antibody targeting GPRC5D×CD3
Study Sites: West China Hospital, Sichuan University、Zhongshan Hospital, Fudan University、Jiangsu Province Hospital、Anhui Provincial Hospital 等 12 家中心
Phase IIICTR20260453
RecruitingA Multicenter, Open-label, Randomized Phase III Clinical Trial Comparing the Efficacy and Safety of GR1803 Injection Versus Daratumumab + Pomalidomide + Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received 1-3 Prior Lines of Therapy (Including Lenalidomide and a Proteasome Inhibitor)
Population: Relapsed/refractory
Target: BCMA-targeting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、Henan Cancer Hospital、Shengjing Hospital of China Medical University 等 67 家中心
Phase Ib/IICTR20232814
RecruitingAn Open-Label, Multicenter Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of OriCAR-017 in Participants with Relapsed/Refractory Multiple Myeloma (MERCURY)
Population: Relapsed/refractory
Target: GPRC5D-targeted CAR-T
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Shanghai Tongji Hospital、Jiangsu Province Hospital、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 等 8 家中心
Phase 3CTR20200081
RecruitingA Phase 3, Multicenter, Randomized, Open-Label Study Comparing Venetoclax Plus Dexamethasone Versus Pomalidomide Plus Dexamethasone in Participants with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Oral small molecule targeted drug (BCL-2 inhibitor)
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Guangdong Provincial People's Hospital、The First Affiliated Hospital of Soochow University、Peking Union Medical College Hospital 等 19 家中心
Phase I/IICTR20232974
RecruitingA Multicenter, Open-label, Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D × CD3 bispecific antibody
Study Sites: Peking University People's Hospital、The First Affiliated Hospital of Henan University of Science and Technology、Qingdao Municipal Hospital、Shenzhen Second People's Hospital 等 21 家中心
Phase I/IICTR20240206
RecruitingA Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MBS314 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Trispecific antibody targeting BCMA, GPRC5D, and CD3
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Beijing Chaoyang Hospital, Capital Medical University、Sun Yat-sen University Cancer Center、Shandong Cancer Hospital 等 11 家中心
Phase IIICTR20262035
RecruitingA Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Study of IBI3003 Versus Investigator's Choice of Regimen (DPd or PVd) on the Efficacy and Safety in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D/BCMA/CD3 trispecific antibody
Study Sites: Zhongshan Hospital, Fudan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The Affiliated Hospital of Xuzhou Medical University 等 45 家中心
Phase ICTR20242943
RecruitingA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HP-001 Capsules in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
Population: Relapsed/refractory
Target: Small-molecule chemical drug
Study Sites: West China Hospital, Sichuan University、Henan Cancer Hospital、The First Affiliated Hospital of Nanchang University、Anhui Provincial Cancer Hospital 等 26 家中心
Phase I/IICTR20233843
RecruitingA Multicenter, Open-label, Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CM313(SC) Injection as Monotherapy and in Combination with Other Antineoplastic Therapies in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: Recombinant humanized anti-CD38 monoclonal antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Hunan Cancer Hospital 等 16 家中心
Early Exploratory Clinical StudyNCT07715630
RecruitingIn Vivo-Generated PICX Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: Relapsed/refractory multiple myeloma (RRMM)
Study Sites: The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Phase IbCTR20251016
RecruitingA Phase Ib, Open-Label, Single-Arm, Multicenter Study Evaluating the Pharmacokinetics, Safety, and Efficacy of CEVOSTAMAB in Chinese Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: T-cell redirecting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin Institute of Hematology)、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Nanchang University、The First Affiliated Hospital of Wenzhou Medical University
Phase Ib/IICTR20221467
RecruitingA Phase Ib/II Clinical Study of CBM.BCMA Chimeric Antigen Receptor T-cell Injection (C-CAR088) in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Autologous anti-BCMA CAR-T
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin Institute of Hematology)
Phase IIICTR20242452
RecruitingA Phase III, Multicenter, Randomized, Open-Label Study Comparing Etentamig with Available Standard of Care Therapies in Participants with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Population: Relapsed/refractory
Target: BCMA × CD3 bispecific T-cell engager (BiTE)
Study Sites: The First Affiliated Hospital of Nanchang University、Shanghai Tongji Hospital、Sun Yat-sen University Cancer Center、Henan Cancer Hospital 等 19 家中心
Phase IIICTR20241042
RecruitingA Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (Stage 1)
Population: Relapsed/refractory
Target: Recombinant humanized anti-CD38 monoclonal antibody
Study Sites: The First Affiliated Hospital of Soochow University、Beijing Chaoyang Hospital, Capital Medical University、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Tianjin Medical University Cancer Institute and Hospital 等 12 家中心
Phase Ib/IIaCTR20222476
RecruitingA Phase Ib/IIa, Open-Label, Dose-Escalation and Expansion Study Evaluating the Safety and Efficacy of an Anti-CD38 Antibody-Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: antibody-drug conjugate (ADC)
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、The First Affiliated Hospital, Sun Yat-sen University、Beijing Chaoyang Hospital, Capital Medical University、Peking University Third Hospital
Phase ICTR20232373
RecruitingA Phase I Clinical Trial of QLS32015 for Injection Evaluating Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D × CD3-targeting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Shandong Cancer Hospital affiliated to Shandong First Medical University、The First Affiliated Hospital of Nanchang University 等 11 家中心
Phase IIICTR20221556
RecruitingA Phase III, Multicenter, Open-label, Randomized Study Evaluating the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 8)
Population: Relapsed/refractory
Target: Antibody-drug conjugate (ADC) targeting BCMA
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sun Yat-sen University Cancer Center、Shengjing Hospital of China Medical University、Peking University Third Hospital 等 11 家中心
Phase ICTR20260125
RecruitingA Phase I, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HL17 in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Recombinant anti-BCMA and CD3 bispecific antibody injection
Study Sites: PKU Healthcare Luzhong Hospital